Trials / Completed
CompletedNCT01772524
Safety, Efficacy and Pharmacokinetics of ALD403
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALD403 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-12-01
- Completion
- 2014-02-01
- First posted
- 2013-01-21
- Last updated
- 2016-01-08
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01772524. Inclusion in this directory is not an endorsement.